News | February 20, 2008

Accumetrics Gets $28.8 Million for GRAVITAS Trial

February 21, 2008 - Accumetrics Inc. has raised $28.8 million in its Series D financing, which will enable the company to initiate the GRAVITAS study and develop solutions for personalized medicine for cardiovascular disease.

The syndicate was led by Arnerich Massena & Associates, Inc. and BBT Fund, L.P. Also participating in the round were previous investors: Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.

Accumetrics has multiple reimbursed and FDA cleared products to assist physicians in their care of patients regarding antiplatelet medications.
Because millions of patients are prescribed Plavix and aspirin to lower the risk of coronary heart disease worldwide, there is reportedly need to tailor antiplatelet therapy and improve clinical outcome. Under the direction of the Scripps Advanced Clinical Trials center, Accumetrics is sponsoring a 6000 patient, multi-center trial, called GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) to establish platelet function testing with VerifyNow as the standard of care. The Executive Committee comprises a group of physicians in the field of cardiology and includes Matthew Price, M.D., principal investigator), Eric Topol, M.D., Paul Teirstein, M.D., and Christopher Cannon, M.D.

"The GRAVITAS trial, using VerifyNow to gauge patients' response is prototypic of the future of individualized medicine," said Matthew Price, M.D., director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA. "Not everyone responds the same way to current anti-platelet medications, so why should we treat our patients as if they did? The results of this trial will help physicians make clinical decisions to maximize safety and improve outcomes for a large number of patients taking anti-platelet therapy."

For more information:

Related Content

Toshiba Aquilion Prime CT

Toshiba's Aquilion Prime CT system

News | August 01, 2014
August 1, 2014 — Thousands of healthcare providers weighed in to identify this year's top-performing vendor solutions...

Siemens unveiled the world's first wireless ultrasound transducer at RSNA 2012.

Feature | December 07, 2012 | Dave Fornell
There were several evident trends on the show floor at RSNA 2012, including interest in software fueled by Stage 1 and...
News | July 10, 2012
July 10, 2012 — New and updated evidence-based guidelines to help healthcare providers choose the most appropriate...

Image from a Siemens Somatom Definition AS 64-slice CT scanner.

News | June 25, 2012
June 25, 2012 — KLAS released the 2012 Best in KLAS Awards: Medical Equipment and Infrastructure report, which details...
News | June 17, 2011
June 17, 2011 — KLAS today announced the release of their highly anticipated "2011 Top 20 Best in KLAS Awards: Medical...
Technology | October 07, 2009
Radcal's new ACCU-PRO Multi-Purpose Analyzer with basic and advanced dose features kVp and mAs functions for...
News | December 13, 2007
December 14, 2007 - Boston Scientific Corp.
News | September 13, 2007
September 14, 2007 - For many years, American Heart Association research has supported education and training program
Technology | April 04, 2007
The AXIOM Sensis XP combines both hemo and advanced EP applications in one system.
Technology | March 29, 2007
Boston Scientific announced it will begin a new Plavix Compliance program aimed at helping patients with drug eluting
Overlay Init